Vir Biotechnology Announces Change to Virtual Format for 2020 Annual Meeting of StockholdersGlobeNewsWire • 05/08/20
Vir Biotechnology and Alnylam Pick a Coronavirus Vaccine Candidate to PursueThe Motley Fool • 05/04/20
VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 TrialGlobeNewsWire • 04/15/20
GlaxoSmithKline and Vir Biotechnology Jump in Race to Treat and Prevent COVID-19The Motley Fool • 04/06/20
Biogen and Vir Biotechnology to Collaborate to Find a Treatment for the CoronavirusThe Motley Fool • 03/12/20
Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19GlobeNewsWire • 03/12/20
Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against CoronavirusesGlobeNewsWire • 03/11/20